Fmr Llc - Sep 19, 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Other*
Signature
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
NMRA
Transactions as of
Sep 19, 2023
Transactions value $
$0
Form type
4
Date filed
9/21/2023, 08:30 AM
Previous filing
Sep 14, 2023
Next filing
Oct 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Conversion of derivative security +3.48M +181.81% 5.39M Sep 19, 2023 F-Prime Capital Partners Life Sciences Fund VII LP F1
transaction NMRA Common Stock Conversion of derivative security +85K +1.58% 5.47M Sep 19, 2023 F-Prime Capital Partners Life Sciences Fund VII LP F1
transaction NMRA Common Stock Conversion of derivative security +63.7K 63.7K Sep 19, 2023 F-Prime Inc. F1
transaction NMRA Common Stock Conversion of derivative security +88.3K 88.3K Sep 19, 2023 FBRI LLC F1
holding NMRA Common Stock 1.91M Sep 19, 2023 F-Prime Capital Partners Life Sciences Fund VII LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Series A-2 Preferred Stock Conversion of derivative security -63.7K -100% 0 Sep 19, 2023 Common Stock 63.7K F-Prime Inc. F1
transaction NMRA Series A-2 Preferred Stock Conversion of derivative security -3.48M -100% 0 Sep 19, 2023 Common Stock 3.48M F-Prime Capital Partners Life Sciences Fund VII LP F1
transaction NMRA Series B Preferred Stock Conversion of derivative security -85K -100% 0 Sep 19, 2023 Common Stock 85K F-Prime Capital Partners Life Sciences Fund VII LP F1
transaction NMRA Series A-2 Preferred Stock Conversion of derivative security -88.3K -100% 0 Sep 19, 2023 Common Stock 88.3K FBRI LLC F1

Fmr Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: FBRI LLC and F-Prime Inc are wholly-owned subsidiaries of FMR LLC. F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.